Literature DB >> 8284266

Differential binding of opioid peptides and other drugs to two subtypes of opioid delta ncx binding sites in mouse brain: further evidence for delta receptor heterogeneity.

H Xu1, J S Partilla, B R de Costa, K C Rice, R B Rothman.   

Abstract

Research into the functional role of the opioid delta receptor has intensified with the recent in vivo identification of delta receptor subtypes, termed delta 1 and delta 2, which mediate antinociception in the mouse. A variety of data also support the hypothesis of an opioid receptor complex composed of distinct, yet interacting, mu, delta, and perhaps kappa binding sites. This model postulates two classes of delta binding sites: a delta binding site not associated with the opioid receptor complex, termed the delta ncx site, and a delta site associated with the receptor complex, termed the delta cx site. A major purpose of this study was to clarify the relationship between the delta ncx binding sites and the delta 1 and delta 2 receptors. Mouse brain membranes were depleted of mu sites by pretreatment with the site-directed acylating agent, BIT, and the delta ncx binding sites were labeled with [3H][D-Ala2,D-Leu5]enkephalin. Binding surface analysis readily resolved two binding sites (delta ncx-1 and delta ncx-2) in the absence and presence of 100 mM NaCl. Control experiments with guanine nucleotides and the ligand-selectivity analysis indicated that the two sites were not two states of a single receptor. Pretreatment of membranes with DALCE, but not [Cys4]deltorphin, decreased [3H] [D-Ala2,D-Leu5]enkephalin and [3H][D-Ser2,Thr6]enkephalin binding. Ligand-selectivity analysis of the two binding sites suggested that neither delta ncx binding site had the characteristics expected of the delta 2 receptor, and that the delta ncx-1 site, but not the delta ncx-2 site, was synonymous with the delta 1 receptor. Moreover, our finding that the racemic nonpeptide delta agonist, BW373U86, had high affinity at and selectivity for the delta ncx-2 site suggests that this site may be a novel delta receptor that mediates some of the effects of BW373U86.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8284266     DOI: 10.1016/0196-9781(93)90064-n

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  7 in total

1.  Heterodimerization of mu and delta opioid receptors: A role in opiate synergy.

Authors:  I Gomes; B A Jordan; A Gupta; N Trapaidze; V Nagy; L A Devi
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

2.  Docking studies suggest ligand-specific delta-opioid receptor conformations.

Authors:  Vuk Micovic; Milovan D Ivanovic; Ljiljana Dosen-Micovic
Journal:  J Mol Model       Date:  2008-12-04       Impact factor: 1.810

3.  Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.

Authors:  H Beaudry; L Gendron; J A Morón
Journal:  Eur J Neurosci       Date:  2015-01-09       Impact factor: 3.386

Review 4.  Molecular Pharmacology of δ-Opioid Receptors.

Authors:  Louis Gendron; Catherine M Cahill; Mark von Zastrow; Peter W Schiller; Graciela Pineyro
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

5.  YFa and analogs: investigation of opioid receptors in smooth muscle contraction.

Authors:  Krishan Kumar; Ritika Goyal; Annu Mudgal; Anita Mohan; Santosh Pasha
Journal:  World J Gastroenterol       Date:  2011-10-28       Impact factor: 5.742

6.  Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.

Authors:  D I Brissett; J L Whistler; R M van Rijn
Journal:  Eur J Pain       Date:  2011-12-19       Impact factor: 3.931

7.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.